If you purchase your insurance from the state or federal marketplace this is important! The 2020 Open Enrollment Period is the yearly period when people can enroll in a health insurance plan. Open Enrollment for the national Health Insurance Marketplace 2020 along with many of the state health insurance marketplaces opens today. Enrollment only runs[...]

Taking a new approach to fighting ALS, a new drug that heals mitochondria in nerve cells is now moving on to in-human studies. This drug, called SBT-272, has been proven to effectively decrease nerve damage in ALS Mouse Models. What is the Mitochondria? About 80% of your body’s energy comes from the part of the[...]

A new oral drug is in development for ALS patients to prevent nerve damage. With few drugs in the clinic for ALS patients today, the potential to have new treatments for ALS is hopeful. A Phase II study was completed by Amylyx Pharmaceuticals for their drug AMX0035. They expect that complete data will be evaluated[...]

NurOwn Stem Cell Therapy for ALS Phase 3 Clinical Trial Notice: This trial is fully accrued as of Friday, October 11th, 2019. NurOwn therapy is an effort to stop neurodegeneration for ALS at its root. It uses a stem cell platform that involves harvesting mesenchymal stem cells (MSC) and was developed by BrainStorm Cell Therapeutics.[...]

A recent study done by researchers at Oregon State University gives us insight into why certain cells in the nervous system are prone to death and decay. To do this, they took a look at proteins that are affecting the cells.  Proteins play a very important role in the life of a cell. One of[...]

Tim Green, a former NFL player, is fighting against ALS and is working tirelessly to find a cure. On 60 Minutes Tim and his son Troy Green, give us insight into Tim’s life and how he deals with ALS. Tim feels that his purpose is to be the best husband, father, lawyer, writer, and businessman[...]

A recent paper was written on Parkinson’s disease showing that two conditions – oxidative stress and proteinopathy –   may help find the cause of ALS and other neurodegenerative diseases. The paper shows that two possible culprits of ALS may, in fact, be working together to destroy neurons in ALS patients. Although it is still unclear[...]

The FDA recently granted the status of ‘orphan drug’ to APB-102, a potential gene therapy for familial ALS. Orphan drug status is given to terminal diseases that affect small numbers of patients.  John Reilly, Chief Executive Officer and co-founder of Apic Bio says they plan to open a clinical trial for APB-102. This trial will[...]

UC San Diego School of Medicine researchers have discovered that prolonged cellular stress, like exposure to toxins, triggers clumping of proteins that affect normal motor neuron function – the nerve cells that control your muscles and the ability to breathe. Published in in Neuron, the researchers noticed that the motor neurons of ALS patients have excessive buildup[...]

This #GivingTuesday is an opportunity to advance a cure by donating to leading edge ALS research. The ALS Crowd Research Initiative is a campaign to find and fund the most promising research for ALS patients who are not obtain their best outcomes with today’s therapies. 100% of your donation will be directed to research. Help[...]